{
    "2021-04-27": [
        [
            {
                "time": "",
                "original_text": "上海医药(601607.SH)：SPH8216(TK216)注射液II期临床试验申请获批",
                "features": {
                    "keywords": [
                        "上海医药",
                        "SPH8216",
                        "TK216",
                        "注射液",
                        "II期临床试验",
                        "获批"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "上海医药(02607.HK)：SPH8216(TK216)注射液获得 II 期临床试验批准通知书",
                "features": {
                    "keywords": [
                        "上海医药",
                        "SPH8216",
                        "TK216",
                        "注射液",
                        "II期临床试验",
                        "批准通知书"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "券商晨会观点速递",
                "features": {
                    "keywords": [
                        "券商",
                        "晨会",
                        "观点速递"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "中信建投：再次强调疫苗产业链投资机会",
                "features": {
                    "keywords": [
                        "中信建投",
                        "疫苗",
                        "产业链",
                        "投资机会"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "疫苗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}